Physician profile
Michelle T Chmelecki
NPI 1134456957
$11,861.19
in general payments reported to CMS, 2019-2025
12 companies · $9,536 in 2025
The $9,536 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $548 · 2022: $551 · 2023: $687 · 2024: $538 · 2025: $9,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $8,709 · Food and Beverage: $2,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $8,709.05 |
| Food and Beverage | $2,052.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $8,709.05 | 2025 | Neurostar Tms Therapy System |
| Otsuka America Pharmaceutical, INC. | $876.37 | 2021-2025 | Rexulti |
| Abbvie INC. | $796.86 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $466.09 | 2021-2024 | Trintellix |
| Corium, LLC | $434.88 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $309.97 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $115.95 | 2024-2025 | Ingrezza |
| Biohaven Pharmaceuticals, INC. | $60.00 | 2021 | |
| Alkermes, INC. | $28.41 | 2025 | Aristada, Lybalvi |
| Lundbeck LLC | $25.77 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.31 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $18.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Chmelecki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.